Cholesterol as a modulator of cannabinoid receptor CB


Journal

Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288

Informations de publication

Date de publication:
12 02 2021
Historique:
received: 12 10 2020
accepted: 20 01 2021
entrez: 13 2 2021
pubmed: 14 2 2021
medline: 15 12 2021
Statut: epublish

Résumé

Signaling through integral membrane G protein-coupled receptors (GPCRs) is influenced by lipid composition of cell membranes. By using novel high affinity ligands of human cannabinoid receptor CB

Identifiants

pubmed: 33580091
doi: 10.1038/s41598-021-83245-6
pii: 10.1038/s41598-021-83245-6
pmc: PMC7881127
doi:

Substances chimiques

Receptor, Cannabinoid, CB2 0
Cholesterol 97C5T2UQ7J

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

3706

Références

Jastrzebska, B., Debinski, A., Filipek, S. & Palczewski, K. Role of membrane integrity on G protein-coupled receptors: Rhodopsin stability and function. Prog. Lipid Res. 50, 267–277. https://doi.org/10.1016/j.plipres.2011.03.002 (2011).
doi: 10.1016/j.plipres.2011.03.002 pubmed: 21435354 pmcid: 3114187
Marino, K. A., Prada-Gracia, D., Provasi, D. & Filizola, M. Impact of lipid composition and receptor conformation on the spatio-temporal organization of mu-opioid receptors in a multi-component plasma membrane model. PLoS Comput. Biol. 12, e1005240. https://doi.org/10.1371/journal.pcbi.1005240 (2016).
doi: 10.1371/journal.pcbi.1005240 pubmed: 27959924 pmcid: 5154498
Salas-Estrada, L. A., Leioatts, N., Romo, T. D. & Grossfield, A. Lipids alter rhodopsin function via ligand-like and solvent-like interactions. Biophys. J. 114, 355–367. https://doi.org/10.1016/j.bpj.2017.11.021 (2018).
doi: 10.1016/j.bpj.2017.11.021 pubmed: 29401433 pmcid: 5984976
Escriba, P. V. et al. Role of lipid polymorphism in G protein-membrane interactions: Nonlamellar-prone phospholipids and peripheral protein binding to membranes. Proc. Natl. Acad. Sci. U.S.A. 94, 11375–11380. https://doi.org/10.1073/pnas.94.21.11375 (1997).
doi: 10.1073/pnas.94.21.11375 pubmed: 9326617 pmcid: 23471
Maxfield, F. R. & van Meer, G. Cholesterol, the central lipid of mammalian cells. Curr. Opin. Cell. Biol. 22, 422–429. https://doi.org/10.1016/j.ceb.2010.05.004 (2010).
doi: 10.1016/j.ceb.2010.05.004 pubmed: 20627678 pmcid: 2910236
Chini, B. & Parenti, M. G-protein-coupled receptors, cholesterol and palmitoylation: Facts about fats. J. Mol. Endocrinol. 42, 371–379. https://doi.org/10.1677/JME-08-0114 (2009).
doi: 10.1677/JME-08-0114 pubmed: 19131499
Manna, M. et al. Mechanism of allosteric regulation of beta2-adrenergic receptor by cholesterol. Elife https://doi.org/10.7554/eLife.18432 (2016).
doi: 10.7554/eLife.18432 pubmed: 27897972 pmcid: 5182060
Guixa-Gonzalez, R. et al. Membrane cholesterol access into a G-protein-coupled receptor. Nat. Commun. 8, 14505. https://doi.org/10.1038/ncomms14505 (2017).
doi: 10.1038/ncomms14505 pubmed: 28220900 pmcid: 5321766
Hefti, F. F. Requirements for a lead compound to become a clinical candidate. BMC Neurosci. 9, S7. https://doi.org/10.1186/1471-2202-9-S3-S7 (2008).
doi: 10.1186/1471-2202-9-S3-S7 pubmed: 19091004 pmcid: 2604885
Dawaliby, R. et al. Phosphatidylethanolamine is a key regulator of membrane fluidity in eukaryotic cells. J. Biol. Chem. 291, 3658–3667. https://doi.org/10.1074/jbc.M115.706523 (2016).
doi: 10.1074/jbc.M115.706523 pubmed: 26663081
Marheineke, K., Grunewald, S., Christie, W. & Reilander, H. Lipid composition of Spodoptera frugiperda (Sf9) and Trichoplusia ni (Tn) insect cells used for baculovirus infection. FEBS Lett. 441, 49–52 (1998).
doi: 10.1016/S0014-5793(98)01523-3
Warnock, D. E. et al. Determination of plasma membrane lipid mass and composition in cultured Chinese hamster ovary cells using high gradient magnetic affinity chromatography. J. Biol. Chem. 268, 10145–10153 (1993).
doi: 10.1016/S0021-9258(18)82184-6
Oursel, D. et al. Lipid composition of membranes of Escherichia coli by liquid chromatography/tandem mass spectrometry using negative electrospray ionization. Rapid Commun. Mass Spectrom. 21, 1721–1728. https://doi.org/10.1002/rcm.3013 (2007).
doi: 10.1002/rcm.3013 pubmed: 17477452
Morein, S., Andersson, A. S., Rilfors, L. & Lindblom, G. Wild-type Escherichia coli cells regulate the membrane lipid composition in a “window” between gel and non-lamellar structures. J. Biol. Chem. 271, 6801–6809. https://doi.org/10.1074/jbc.271.12.6801 (1996).
doi: 10.1074/jbc.271.12.6801 pubmed: 8636103
Vauquelin, G. Cell membranes and how long drugs may exert beneficial pharmacological activity in vivo. Br. J. Clin. Pharmacol. 82, 673–682. https://doi.org/10.1111/bcp.12996 (2016).
doi: 10.1111/bcp.12996 pubmed: 27135195 pmcid: 5338106
Jacobson, K. A. New paradigms in GPCR drug discovery. Biochem. Pharmacol. 98, 541–555. https://doi.org/10.1016/j.bcp.2015.08.085 (2015).
doi: 10.1016/j.bcp.2015.08.085 pubmed: 26265138 pmcid: 4967540
Overington, J. P., Al-Lazikani, B. & Hopkins, A. L. How many drug targets are there?. Nat. Rev. Drug Discov. 5, 993–996. https://doi.org/10.1038/nrd2199 (2006).
doi: 10.1038/nrd2199 pubmed: 17139284
Yin, H. & Flynn, A. D. Drugging membrane protein interactions. Annu. Rev. Biomed. Eng. 18, 51–76. https://doi.org/10.1146/annurev-bioeng-092115-025322 (2016).
doi: 10.1146/annurev-bioeng-092115-025322 pubmed: 26863923 pmcid: 4968933
Talmont, F., Lebrun, C. & Zajac, J. M. Agonist binding of human mu opioid receptors expressed in the yeast Pichia pastoris: Effect of cholesterol complementation. Neurochem. Int. 132, 104588. https://doi.org/10.1016/j.neuint.2019.104588 (2020).
doi: 10.1016/j.neuint.2019.104588 pubmed: 31704091
Veatch, S. L., Soubias, O., Keller, S. L. & Gawrisch, K. Critical fluctuations in domain-forming lipid mixtures. Proc. Natl. Acad. Sci. U.S.A. 104, 17650–17655. https://doi.org/10.1073/pnas.0703513104 (2007).
doi: 10.1073/pnas.0703513104 pubmed: 17962417 pmcid: 2077022
Chen, Z. & Rand, R. P. The influence of cholesterol on phospholipid membrane curvature and bending elasticity. Biophys. J. 73, 267–276. https://doi.org/10.1016/S0006-3495(97)78067-6 (1997).
doi: 10.1016/S0006-3495(97)78067-6 pubmed: 9199791 pmcid: 1180928
Pan, J., Tristram-Nagle, S. & Nagle, J. F. Effect of cholesterol on structural and mechanical properties of membranes depends on lipid chain saturation. Phys. Rev. E Stat. Nonlin. Soft Matter. Phys. 80, 021931. https://doi.org/10.1103/PhysRevE.80.021931 (2009).
doi: 10.1103/PhysRevE.80.021931 pubmed: 19792175 pmcid: 2756665
Rouviere, E., Arnarez, C., Yang, L. & Lyman, E. Identification of two new cholesterol interaction sites on the A2A adenosine receptor. Biophys. J. 113, 2415–2424. https://doi.org/10.1016/j.bpj.2017.09.027 (2017).
doi: 10.1016/j.bpj.2017.09.027 pubmed: 29211995 pmcid: 5738547
Gimpl, G. Interaction of G protein coupled receptors and cholesterol. Chem. Phys. Lipids 199, 61–73. https://doi.org/10.1016/j.chemphyslip.2016.04.006 (2016).
doi: 10.1016/j.chemphyslip.2016.04.006 pubmed: 27108066
Sengupta, D., Prasanna, X., Mohole, M. & Chattopadhyay, A. Exploring GPCR-lipid interactions by molecular dynamics simulations: Excitements, challenges, and the way forward. J. Phys. Chem. B 122, 5727–5737. https://doi.org/10.1021/acs.jpcb.8b01657 (2018).
doi: 10.1021/acs.jpcb.8b01657 pubmed: 29685028
Legler, D. F. et al. Modulation of chemokine receptor function by cholesterol: New prospects for pharmacological intervention. Mol. Pharmacol. 91, 331–338. https://doi.org/10.1124/mol.116.107151 (2017).
doi: 10.1124/mol.116.107151 pubmed: 28082305
Bari, M., Paradisi, A., Pasquariello, N. & Maccarrone, M. Cholesterol-dependent modulation of type 1 cannabinoid receptors in nerve cells. J. Neurosci. Res. 81, 275–283. https://doi.org/10.1002/jnr.20546 (2005).
doi: 10.1002/jnr.20546 pubmed: 15920744
Oddi, S. et al. Functional characterization of putative cholesterol binding sequence (CRAC) in human type-1 cannabinoid receptor. J Neurochem. 116, 858–865. https://doi.org/10.1111/j.1471-4159.2010.07041.x (2011).
doi: 10.1111/j.1471-4159.2010.07041.x pubmed: 21214565
Bari, M. et al. Effect of lipid rafts on Cb2 receptor signaling and 2-arachidonoyl-glycerol metabolism in human immune cells. J. Immunol. 177, 4971–4980 (2006).
doi: 10.4049/jimmunol.177.8.4971
Turcotte, C., Blanchet, M. R., Laviolette, M. & Flamand, N. The CB2 receptor and its role as a regulator of inflammation. Cell. Mol. Life Sci. 73, 4449–4470. https://doi.org/10.1007/s00018-016-2300-4 (2016).
doi: 10.1007/s00018-016-2300-4 pubmed: 27402121 pmcid: 5075023
Li, X. et al. Crystal structure of the human cannabinoid receptor CB2. Cell 176, 459–467. https://doi.org/10.1016/j.cell.2018.12.011 (2019).
doi: 10.1016/j.cell.2018.12.011 pubmed: 30639103 pmcid: 6713262
Yao, B. B. et al. Characterization of a cannabinoid CB2 receptor-selective agonist, A-836339 [2,2,3,3-tetramethyl-cyclopropanecarboxylic acid [3-(2-methoxy-ethyl)-4,5-dimethyl-3H-thiazol-(2Z)-ylidene]-amide], using in vitro pharmacological assays, in vivo pain models, and pharmacological magnetic resonance imaging. J. Pharmacol. Exp. Ther. 328, 141–151. https://doi.org/10.1124/jpet.108.145011 (2009).
doi: 10.1124/jpet.108.145011 pubmed: 18931146
Yeliseev, A. A. Methods for recombinant expression and functional characterization of human cannabinoid receptor Cb2. Comput. Struct. Biotechnol. J. 2, 2. https://doi.org/10.5936/csbj.201303011 (2013).
doi: 10.5936/csbj.201303011
Yeliseev, A. A., Wong, K. K., Soubias, O. & Gawrisch, K. Expression of human peripheral cannabinoid receptor for structural studies. Protein Sci. 14, 2638–2653. https://doi.org/10.1110/ps.051550305 (2005).
doi: 10.1110/ps.051550305 pubmed: 16195551 pmcid: 2253291
Parathath, S. et al. Changes in plasma membrane properties and phosphatidylcholine subspecies of insect Sf9 cells due to expression of scavenger receptor class B, type I, and CD36. J. Biol. Chem. 279, 41310–41318. https://doi.org/10.1074/jbc.M404952200 (2004).
doi: 10.1074/jbc.M404952200 pubmed: 15280390
Gimpl, G., Klein, U., Reilander, H. & Fahrenholz, F. Expression of the human oxytocin receptor in baculovirus-infected insect cells: High-affinity binding is induced by a cholesterol-cyclodextrin complex. Biochemistry 34, 13794–13801. https://doi.org/10.1021/bi00042a010 (1995).
doi: 10.1021/bi00042a010 pubmed: 7577972
Huang, Z. & London, E. Cholesterol lipids and cholesterol-containing lipid rafts in bacteria. Chem. Phys. Lipids 199, 11–16. https://doi.org/10.1016/j.chemphyslip.2016.03.002 (2016).
doi: 10.1016/j.chemphyslip.2016.03.002 pubmed: 26964703 pmcid: 4972651
Liu, S. L. et al. Orthogonal lipid sensors identify transbilayer asymmetry of plasma membrane cholesterol. Nat. Chem. Biol. 13, 268–274. https://doi.org/10.1038/nchembio.2268 (2017).
doi: 10.1038/nchembio.2268 pubmed: 28024150
Mahammad, S. & Parmryd, I. Cholesterol depletion using methyl-beta-cyclodextrin. Methods Mol. Biol. 1232, 91–102. https://doi.org/10.1007/978-1-4939-1752-5_8 (2015).
doi: 10.1007/978-1-4939-1752-5_8 pubmed: 25331130
Zidovetzki, R. & Levitan, I. Use of cyclodextrins to manipulate plasma membrane cholesterol content: Evidence, misconceptions and control strategies. Biochim. Biophys. Acta 1768, 1311–1324. https://doi.org/10.1016/j.bbamem.2007.03.026 (2007).
doi: 10.1016/j.bbamem.2007.03.026 pubmed: 17493580 pmcid: 1948080
Yeliseev, A., Zoubak, L. & Schmidt, T. G. M. Application of Strep-Tactin XT for affinity purification of Twin-Strep-tagged CB2, a G protein-coupled cannabinoid receptor. Protein Expr. Purif. 131, 109–118. https://doi.org/10.1016/j.pep.2016.11.006 (2017).
doi: 10.1016/j.pep.2016.11.006 pubmed: 27867058
Yeliseev, A. et al. Thermostability of a recombinant G protein-coupled receptor expressed at high level in mammalian cell culture. Sci. Rep. 10, 16805. https://doi.org/10.1038/s41598-020-73813-7 (2020).
doi: 10.1038/s41598-020-73813-7 pubmed: 33033368 pmcid: 7546613
Vukoti, K., Kimura, T., Macke, L., Gawrisch, K. & Yeliseev, A. Stabilization of functional recombinant cannabinoid receptor CB2 in detergent micelles and lipid bilayers. PLoS ONE 7, e46290. https://doi.org/10.1371/journal.pone.0046290 (2012).
doi: 10.1371/journal.pone.0046290 pubmed: 23056277 pmcid: 3463599
Xing, C. et al. Cryo-EM structure of the human cannabinoid receptor CB2-Gi signaling complex. Cell https://doi.org/10.1016/j.cell.2020.01.007 (2020).
doi: 10.1016/j.cell.2020.01.007 pubmed: 32259487 pmcid: 8247115
Huang, W. et al. Structural insights into micro-opioid receptor activation. Nature 524, 315–321. https://doi.org/10.1038/nature14886 (2015).
doi: 10.1038/nature14886 pubmed: 26245379 pmcid: 4639397
Salari, R., Joseph, T., Lohia, R., Henin, J. & Brannigan, G. A streamlined, general approach for computing ligand binding free energies and its application to GPCR-bound cholesterol. J. Chem. Theory Comput. 14, 6560–6573. https://doi.org/10.1021/acs.jctc.8b00447 (2018).
doi: 10.1021/acs.jctc.8b00447 pubmed: 30358394 pmcid: 6467757
Kimura, T. et al. Recombinant cannabinoid type 2 receptor in liposome model activates g protein in response to anionic lipid constituents. J. Biol. Chem. 287, 4076–4087. https://doi.org/10.1074/jbc.M111.268425 (2012).
doi: 10.1074/jbc.M111.268425 pubmed: 22134924
Mouritsen, O. G. & Zuckermann, M. J. What’s so special about cholesterol?. Lipids 39, 1101–1113. https://doi.org/10.1007/s11745-004-1336-x (2004).
doi: 10.1007/s11745-004-1336-x pubmed: 15726825
Niu, S. L., Mitchell, D. C. & Litman, B. J. Manipulation of cholesterol levels in rod disk membranes by methyl-beta-cyclodextrin: Effects on receptor activation. J. Biol. Chem. 277, 20139–20145. https://doi.org/10.1074/jbc.M200594200 (2002).
doi: 10.1074/jbc.M200594200 pubmed: 11889130
Cantor, R. S. The lateral pressure profile in membranes: A physical mechanism of general anesthesia. Biochemistry 36, 2339–2344. https://doi.org/10.1021/bi9627323 (1997).
doi: 10.1021/bi9627323 pubmed: 9054538
Andersen, O. S. & Koeppe, R. E. Bilayer thickness and membrane protein function: An energetic perspective. Annu. Rev. Biophys. Biomol. Struct. 36, 107–130. https://doi.org/10.1146/annurev.biophys.36.040306.132643 (2007).
doi: 10.1146/annurev.biophys.36.040306.132643 pubmed: 17263662
Yeagle, P. L. Modulation of membrane function by cholesterol. Biochimie 73, 1303–1310. https://doi.org/10.1016/0300-9084(91)90093-g (1991).
doi: 10.1016/0300-9084(91)90093-g pubmed: 1664240
Pucadyil, T. J. & Chattopadhyay, A. Role of cholesterol in the function and organization of G-protein coupled receptors. Prog. Lipid Res. 45, 295–333. https://doi.org/10.1016/j.plipres.2006.02.002 (2006).
doi: 10.1016/j.plipres.2006.02.002 pubmed: 16616960
Sohlenkamp, C. & Geiger, O. Bacterial membrane lipids: Diversity in structures and pathways. FEMS Microbiol. Rev. 40, 133–159. https://doi.org/10.1093/femsre/fuv008 (2016).
doi: 10.1093/femsre/fuv008 pubmed: 25862689
Hua, T. et al. Crystal structure of the human cannabinoid receptor CB1. Cell 167, 750–762. https://doi.org/10.1016/j.cell.2016.10.004 (2016).
doi: 10.1016/j.cell.2016.10.004 pubmed: 27768894 pmcid: 5322940
Krishna Kumar, K. et al. Structure of a signaling cannabinoid receptor 1-G protein complex. Cell 176, 448–458. https://doi.org/10.1016/j.cell.2018.11.040 (2019).
doi: 10.1016/j.cell.2018.11.040 pubmed: 30639101
Reggio, P. H. Endocannabinoid binding to the cannabinoid receptors: What is known and what remains unknown. Curr. Med. Chem. 17, 1468–1486. https://doi.org/10.2174/092986710790980005 (2010).
doi: 10.2174/092986710790980005 pubmed: 20166921 pmcid: 4120766
Ehrhart, J. et al. Stimulation of cannabinoid receptor 2 (CB2) suppresses microglial activation. J. Neuroinflam. 2, 29. https://doi.org/10.1186/1742-2094-2-29 (2005).
doi: 10.1186/1742-2094-2-29
Kishimoto, S. et al. Endogenous cannabinoid receptor ligand induces the migration of human natural killer cells. J. Biochem. 137, 217–223. https://doi.org/10.1093/jb/mvi021 (2005).
doi: 10.1093/jb/mvi021 pubmed: 15749836
Rudd-Schmidt, J. A. et al. Lipid order and charge protect killer T cells from accidental death. Nat. Commun. 10, 5396. https://doi.org/10.1038/s41467-019-13385-x (2019).
doi: 10.1038/s41467-019-13385-x pubmed: 31776337 pmcid: 6881447
Yeliseev, A. A. & Vukoti, K. in Production of membrane proteins (ed A.S. Robinson) 219–248 (Wiley-VCH, 2011).
Horti, A. G. et al. Synthesis and biodistribution of [11C]A-836339, a new potential radioligand for PET imaging of cannabinoid type 2 receptors (CB2). Bioorg. Med. Chem. 18, 5202–5207. https://doi.org/10.1016/j.bmc.2010.05.058 (2010).
doi: 10.1016/j.bmc.2010.05.058 pubmed: 20554448 pmcid: 2903661
Yeliseev, A. Expression and preparation of a G-protein-coupled cannabinoid receptor CB2 for NMR structural studies. Curr. Protoc. Protein Sci. 96, e83. https://doi.org/10.1002/cpps.83 (2019).
doi: 10.1002/cpps.83 pubmed: 30624864 pmcid: 6579622
Cinar, R. et al. Hybrid inhibitor of peripheral cannabinoid-1 receptors and inducible nitric oxide synthase mitigates liver fibrosis. JCI Insight https://doi.org/10.1172/jci.insight.87336 (2016).
doi: 10.1172/jci.insight.87336 pubmed: 27525312 pmcid: 4979564
Iyer, M. R. et al. Structural basis of species-dependent differential affinity of 6-alkoxy-5-aryl-3-pyridinecarboxamide cannabinoid-1 receptor antagonists. Mol. Pharmacol. 88, 238–244 (2015).
doi: 10.1124/mol.115.098541
Beckner, R. L., Zoubak, L., Hines, K. G., Gawrisch, K. & Yeliseev, A. A. Probing thermostability of detergent-solubilized CB2 receptor by parallel G protein-activation and ligand-binding assays. J. Biol. Chem. 295, 181–190. https://doi.org/10.1074/jbc.RA119.010696 (2020).
doi: 10.1074/jbc.RA119.010696 pubmed: 31776188
Huang, J. & MacKerell, A. D. Jr. CHARMM36 all-atom additive protein force field: Validation based on comparison to NMR data. J. Comput. Chem. 34, 2135–2145. https://doi.org/10.1002/jcc.23354 (2013).
doi: 10.1002/jcc.23354 pubmed: 23832629 pmcid: 3800559
68M. J. Frisch, G. W. T., H. B. Schlegel, G. E. Scuseria, M. A. Robb, J. R. Cheeseman, G. Scalmani, V. Barone, G. A. Petersson, H. Nakatsuji, X. Li, M. Caricato, A. Marenich, J. Bloino, B. G. Janesko, R. Gomperts, B. Mennucci, H. P. Hratchian, J. V. Ortiz, A. F. Izmaylov, J. L. Sonnenberg, D. Williams-Young, F. Ding, F. Lipparini, F. Egidi, J. Goings, B. Peng, A. Petrone, T. Henderson, D. Ranasinghe, V. G. Zakrzewski, J. Gao, N. Rega, G. Zheng, W. Liang, M. Hada, M. Ehara, K. Toyota, R. Fukuda, J. Hasegawa, M. Ishida, T. Nakajima, Y. Honda, O. Kitao, H. Nakai, T. Vreven, K. Throssell, J. A. Montgomery, Jr., J. E. Peralta, F. Ogliaro, M. Bearpark, J. J. Heyd, E. Brothers, K. N. Kudin, V. N. Staroverov, T. Keith, R. Kobayashi, J. Normand, K. Raghavachari, A. Rendell, J. C. Burant, S. S. Iyengar, J. Tomasi, M. Cossi, J. M. Millam, M. Klene, C. Adamo, R. Cammi, J. W. Ochterski, R. L. Martin, K. Morokuma, O. Farkas, J. B. Foresman, and D. J. Fox. Gaussian 09, Revision A02. Gaussian, Inc., (2016).
Vanommeslaeghe, K. et al. CHARMM general force field: A force field for drug-like molecules compatible with the CHARMM all-atom additive biological force fields. J. Comput. Chem. 31, 671–690. https://doi.org/10.1002/jcc.21367 (2010).
doi: 10.1002/jcc.21367 pubmed: 19575467 pmcid: 2888302
Lomize, M. A., Pogozheva, I. D., Joo, H., Mosberg, H. I. & Lomize, A. L. OPM database and PPM web server: Resources for positioning of proteins in membranes. Nucleic Acids Res. 40, D370-376. https://doi.org/10.1093/nar/gkr703 (2012).
doi: 10.1093/nar/gkr703 pubmed: 21890895
Lee, J. et al. CHARMM-GUI input generator for NAMD, GROMACS, AMBER, OpenMM, and CHARMM/OpenMM simulations using the CHARMM36 additive force field. J. Chem. Theory Comput. 12, 405–413. https://doi.org/10.1021/acs.jctc.5b00935 (2016).
doi: 10.1021/acs.jctc.5b00935 pubmed: 26631602

Auteurs

Alexei Yeliseev (A)

National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health, Bethesda, MD, 20852, USA. yeliseeva@mail.nih.gov.

Malliga R Iyer (MR)

National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health, Bethesda, MD, 20852, USA. malliga.iyer@nih.gov.

Thomas T Joseph (TT)

Department of Anesthesiology and Critical Care, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, 19104, USA.

Nathan J Coffey (NJ)

National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health, Bethesda, MD, 20852, USA.

Resat Cinar (R)

National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health, Bethesda, MD, 20852, USA.

Lioudmila Zoubak (L)

National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health, Bethesda, MD, 20852, USA.

George Kunos (G)

National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health, Bethesda, MD, 20852, USA.

Klaus Gawrisch (K)

National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health, Bethesda, MD, 20852, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH